Glucarpidase
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Glucarpidase: From Methotrexate Toxicity Rescue to Diabetic Cataract
One-Sentence Summary
Glucarpidase is a recombinant enzyme that breaks down methotrexate in plasma. It is marketed in the US as Voraxaze for rescue from methotrexate toxicity. The TxGNN model predicts it may be effective for diabetic cataract, along with nine other cataract and retinopathy variants. Currently there are 0 clinical trials and 0 publications supporting any of these predictions, so this is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Methotrexate toxicity rescue (taken from the pack’s rationale text; the license record has no indication text) |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA125327) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Based on known information, glucarpidase is a recombinant bacterial carboxypeptidase G2. It hydrolyzes methotrexate into DAMPA and glutamate in plasma.
The review did not find a plausible link between this action and diabetic cataract. Diabetic cataract involves polyol-pathway and oxidative damage to the lens. Glucarpidase acts extracellularly on methotrexate and other folate-like substrates and has no known role in lens biology. At about 83 kDa, it is also unlikely to reach the lens.
The ten predictions look like a systematic graph artifact, not independent signals:
- All ten are cataract or retinopathy variants.
- They sit in a narrow score band of 0.9982–0.9985.
- Seven cataract subtypes share nearly identical scores. Three of them (tetanic, mature and immature cataract) have exactly the same score of 0.99833.
| Rank | Predicted Indication | Score |
|---|---|---|
| 1 | Diabetic cataract | 99.85% |
| 2 | Diabetic retinopathy | 99.84% |
| 3–7 | Tetanic, mature, immature, craniostenosis, and type 2 diabetes-associated cataract | 99.83% |
| 8–9 | Cortical cataract, nuclear senile cataract | 99.83% |
| 10 | Senile cataract | 99.82% |
Diabetic retinopathy has no supporting VEGF or retinal vascular link, and an intravitreal route has no supporting data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125327 | Voraxaze (BTG International Inc.) | Injection, powder, for solution | Not stated in the license record |
The only registered route is injectable.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The 99.85% score is not backed by any trial, publication or plausible mechanism, and it is most likely a knowledge-graph artifact. A large injectable enzyme also has no route to the lens or retina.
To proceed, the following is needed:
- The US package insert (warnings, contraindications and approved indication text), which is missing and blocks safety screening
- Mechanism of action data from DrugBank, to test any biological link to lens or retinal disease
- Any preclinical or clinical evidence for the predicted indications. Without it, there is no basis for advancing beyond a model-only hypothesis.
- A route-compatibility assessment for ocular delivery, which is still pending
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.